People · Operator
Named in public records as an officer, director or promoter · active 2021–2025 · Other, Pharma
| Company | Role | Sector | Stage | Raised · real | Value · est | Tied |
|---|---|---|---|---|---|---|
| Cybin Inc. | — | Other | Series D+ | $200.8M | $871K | 2024 |
| Small Pharma Ltd. | — | Pharma | Seed | $1.9M | $52.8M | 2021 |
George Tziras at the center, the companies they're named on, and every other operator named alongside them — an interlock map of shared founding teams, boards and funds. Name-matched, so treat as a research lead.
People named alongside George Tziras on the same companies — an interlock signal (shared founding team, board, or fund). Name-matched, so verify before acting.
| Operator | Shared | Their companies |
|---|---|---|
| Eric So | 1 | 5 |
| John Kanakis | 1 | 4 |
| Mark Lawson | 1 | 4 |
| Jukka Karjalainen | 1 | 2 |
| Greg Cavers | 1 | 2 |
| Theresa Firestone | 1 | 2 |
| Paul Glavine | 1 | 2 |
| Eric Hoskins | 1 | 2 |
| Douglas Drysdale | 1 | 2 |
| Doug Drysdale | 1 | 2 |
| Jacqueline Poriadjian | 1 | 1 |
| Carol Routledge | 1 | 1 |
| Khalid Howladar | 1 | 1 |
| Marie Claire Layzell | 1 | 1 |
| Peter Rands | 1 | 1 |
| Gabriel Fahel | 1 | 1 |
| Aaron Bartlone | 1 | 1 |
| Grant Froese | 1 | 1 |
| Alex Nivorozhkin | 1 | 1 |
| Gabe Fahel | 1 | 1 |
People are matched by normalized name across records; a common name may merge distinct individuals. Treat as a research lead, the same way modeled valuations are directional, not quoted.